Pfizer’s oral Janus kinase 1 (JAK1) inhibitor, abrocitinib, continues to post strong clinical trial results as a treatment for atopic dermatitis.

Pfizer announced positive results from two Phase III trials, one in moderate-to-severe atopic dermatitis and another in pneumococcal disease.

Gilead Sciences Inc. and Galapagos NV announced that Week 52 data from the registrational Phase 3 FINCH 1 and FINCH 3 trials of filgotinib – an investigational, oral, selective JAK1 inhibitor for the treatment of moderately to severely active rheumatoid arthritis (RA) – are consistent with and support the efficacy, safety and tolerability profiles demonstrated in the Week 12 and 24 analyses presented earlier during 2019.

Pfizer’s oral Janus kinase 1 (JAK1) inhibitor abrocitinib hit the primary endpoint in a second Phase III study in patients 12 and older with moderate to severe atopic dermatitis.

Gilead Sciences announced that a path forward was established to submit a New Drug Application in 2019 for the investigational oral, selective JAK1 inhibitor filgotinib as a rheumatoid arthritis treatment.